戈沙妥珠单抗上市后安全性:基于FAERS的药物警戒研究
本研究基于FDA不良事件报告系统(FAERS)数据库,采用信息成分法评估戈沙妥珠单抗与不良事件(AE)的关联,共检索到1,884份报告,识别出114个涉及20个系统的AE信号。AE中位发生时间约6-7天,超过80%的AE发生在30天内。多因素分析显示男性及结肠炎、肺炎、发热性中性粒细胞减少、发热、脓毒症、脱水、腹泻是导致住院的风险因素(AUC=0.89)。
要点
- 戈沙妥珠单抗相关AE中位发生时间约6-7天,超过80%发生在30天内。
- 共识别114个AE信号,涉及20个系统,需重点监测中性粒细胞减少、腹泻、结肠炎和脓毒症。
- 男性及结肠炎、肺炎、发热性中性粒细胞减少、发热、脓毒症、脱水、腹泻是导致住院的风险因素。
核心结论
- 戈沙妥珠单抗上市后安全性分析识别出114个AE信号,需密切监测中性粒细胞减少、腹泻、结肠炎和脓毒症等不良反应。
研究设计与样本
- 基于FDA不良事件报告系统(FAERS)数据库的回顾性药物警戒研究,共检索到1,884份与戈沙妥珠单抗相关的报告,采用信息成分法评估AE关联,并对所有识别信号进行多因素logistic回归分析以探索导致住院的风险因素。
主要发现
- 共识别114个AE信号,涉及20个系统;AE中位发生时间约6-7天,超过80%的AE发生在30天内。
- 亚组分析显示男性报告14个信号,女性报告110个信号;65岁以下患者报告58个信号,65岁以上报告59个信号,两组共有31个信号。
- 多因素分析显示男性及结肠炎、肺炎、发热性中性粒细胞减少、发热、脓毒症、脱水、腹泻是导致住院的风险因素,AUC为0.89。
- 敏感性分析显示研究具有良好稳健性。
临床怎么用
- 使用戈沙妥珠单抗时应密切监测中性粒细胞减少、腹泻、结肠炎和脓毒症等不良反应,尤其关注治疗开始后30天内的患者。
- 对于男性患者及出现结肠炎、肺炎、发热性中性粒细胞减少、发热、脓毒症、脱水、腹泻的患者,应警惕住院风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sacituzumab govitecan is widely used for the treatment of breast cancer and urothelial carcinoma, but available information regarding adverse events (AEs) is limited. We aim to explore the AE induced by sacituzumab govitecan by mining the FDA Adverse Event Reporting System (FAERS) database. The association between sacituzumab govitecan and AEs was evaluated using the information component. A multivariate logistic regression analysis was conducted for all identified signals to explore the risk factors associated with AEs leading to hospitalization. In total, 1,884 reports related to sacituzumab govitecan were retrieved, and 114 AE signals involving 20 systems were identified. The median time for onset of AEs was ~ 6-7 days after initiating treatment with sacituzumab govitecan, with over 80% of AEs occurring within 30 days. Subgroup analysis revealed that 14 signals were reported in men and 110 in women. There were 58 signals reported in patients under 65 following the use of sacituzumab govitecan, 59 signals in patients over 65, and 31 signals were present in both groups. Multivariable analysis showed that being male and the occurrence of colitis, pneumonitis, febrile neutropenia, pyrexia, sepsis, dehydration, and diarrhea were risk factors leading to hospitalization with an area under the curve (AUC) of 0.89. Additionally, sensitivity analysis revealed that this study had good robustness. This is the first retrospective analysis based on FAERS to review the safety of sacituzumab govitecan. The results highlight the need to closely monitor adverse reactions such as neutropenia, diarrhea, colitis, and sepsis when using sacituzumab govitecan.
引用
- Li X, Zhang L, Hu S, et al. Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2023. PMID: 37994531. doi:10.1002/cpt.3098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。